Patients with type 2 diabetes and the acute coronary syndrome who were on chronic SGLT2 inhibitors presented with significantly lower levels of inflammatory parameters and a smaller size of myocardial necrosis compared to patients who were not treated with gliflozins. Here, SLC5A2 is linked to acute coronary syndrome.